Singapore, Nov. 13 -- As part of Abu Dhabi's efforts to expand its oncology research capabilities and address unmet treatment needs for patients with some of the most complex cancers, the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding (MoU) with NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers.

Announced on the sidelines of the Abu Dhabi Future Health Summit (ADFHS) 2026, the proposed collaboration will strengthen research and clinical expertise in CNS oncology, including brain tumours, rare conditions and paediatric cancers, further cementing the Emirate's pos...